Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited (NYSE American: VNRX) is a multi-national epigenetics company whose news flow centers on the development, validation, and commercialization of nucleosome-based blood tests for human and veterinary medicine. Company updates frequently highlight progress across its Nu.Q® platform, including cancer-focused assays, NETosis-related biomarkers, and companion animal diagnostics.
Readers of this VNRX news page can expect coverage of clinical study results, technology milestones, and collaborations. Recent announcements have described breakthrough clinical data for the Nu.Q® Vet Feline assay in detecting lymphoma in cats, positioning it as a potential simple, affordable blood-based liquid biopsy test for feline cancer. Other news has detailed the first commercial sale of Nu.Q® Cancer assays to a major European cancer center for internal certification ahead of routine clinical use in lung cancer management.
VolitionRx also issues news on its role in sepsis and NETosis research. The company has reported inclusion of its Nu.Q® NETs H3.1 assay as the sole biomarker in a French government-backed real-world program evaluating early detection of sepsis, and has highlighted broader work on NETs biomarkers and point-of-care nucleosome testing. Additional updates cover scientific advances such as its Capture-Seq™ method for enriching ultrashort transcription factor-bound DNA fragments in plasma, which the company positions as a potential foundation for accurate, lower-cost liquid biopsy tests.
Investors and followers will also find announcements on business reviews, licensing and co-marketing agreements with diagnostic companies, capital-raising transactions, and veterinary initiatives such as donations of Nu.Q® Vet Cancer Tests to crisis response dogs. This page aggregates these developments so that readers can track how VolitionRx’s clinical, commercial, and financial activities evolve over time.
VolitionRx (NYSE: VNRX) has announced a virtual investor event scheduled for February 14, 2025, at 8:00 AM ET. The event, titled 'Casting a New Light on Sepsis Management,' will feature presentations from Dr. Andrew Retter, Chief Medical Officer, and Gael Forterre, Chief Commercial Officer.
Dr. Retter will discuss Nu.Q® NETs H3.1, a novel biomarker for early mortality and organ dysfunction in sepsis, which also serves as an independent predictor for renal replacement therapy needs. Recent large-scale study results suggest potential clinical applications in risk stratification and early intervention for critically ill sepsis patients.
Mr. Forterre will provide updates on Volition's commercialization strategies through licensing and sales channels. The event will conclude with a live Q&A session.
VolitionRx (NYSE AMERICAN: VNRX) has announced significant results from a large-scale study of its Nu.Q®NETs H3.1 biomarker in sepsis patients. The study, analyzing plasma samples from 971 patients with sepsis and septic shock, demonstrates that the biomarker can independently predict 28-day mortality and need for renal replacement therapy.
The research reveals higher biomarker levels in septic shock compared to sepsis patients, showing a dose-response relationship with acute kidney injury severity. The study suggests Nu.Q® NETs H3.1's potential for risk stratification and early intervention in critically ill sepsis patients.
The company is currently engaged in commercial discussions with major diagnostic industry players, particularly focusing on the sepsis market. The technology aims to provide simple, cost-effective blood tests for disease diagnosis and monitoring in both humans and animals.
VolitionRx (NYSE AMERICAN: VNRX) has released its 2024 Business Review, highlighting significant achievements in expanding its diagnostic technologies. The company's Nu.Q® Vet Cancer Test reached 20 countries worldwide, with over 110,000 tests sold in the first three quarters of 2024.
Key developments include hosting a Satellite Symposium showcasing Nu.Q® NETs clinical utility in over 3,000 intensive care sepsis patients, strengthening their patent portfolio, and making progress in clinical and research programs within their cancer pillar. The company has initiated commercial discussions for out-licensing opportunities in sepsis and oncology liquid biopsy markets.
Volition also strengthened its Board of Directors with the appointment of Timothy Still as chair and Dr. Ethel Rubin as Independent Director, both bringing significant commercial and financing experience in diagnostics.
VolitionRx (NYSE AMERICAN: VNRX) has appointed LifeSci Advisors (LSA) as its investor relations consultants. The company, which specializes in epigenetics, made this announcement following significant progress in 2024, including the launch of Nu.Q® Vet Cancer Test in the U.S. and Europe through Antech.
The company plans to participate in the 14th Annual LifeSci Partners Corporate Access Event on January 15th, 2025, at the Beacon Grand Hotel in San Francisco, coinciding with the J.P. Morgan Health Care Conference. Volition anticipates multiple financial and value-creating operating milestones in human applications for both cancer and sepsis in 2025.
VolitionRx (NYSE AMERICAN: VNRX) announced results from an 800-patient study showing its Nu.Q® Cancer Test can differentiate between malignant and benign pulmonary nodules found by Low Dose CT (LDCT) scan in lung cancer screening. The study, led by Professor Jin-Shing Chen at National Taiwan University Hospital, revealed that a panel of two Nu.Q® nucleosome quantification assays achieved 92% diagnostic sensitivity and 89% Positive Predictive Value when combined with LDCT screening.
A 500-patient validation study in a real-world setting is planned to begin this year, with completion expected in 2025. If successful, the test could be included in Taiwan's National Lung Cancer Screening Program, potentially reducing unnecessary biopsies and surgeries for patients with benign nodules.
VolitionRx (NYSE AMERICAN: VNRX) has announced a registered direct offering expected to raise up to $1.9 million in gross proceeds. The offering includes the sale of 445,648 shares to company insiders at $0.5722 per share, and 2,857,389 shares with warrants to other investors at the same price.
The offering includes Form A warrants to purchase up to 2,857,389 shares at $0.5722 per share and Form B warrants for up to 1,428,693 shares at $0.71525 per share, both exercisable immediately with a 5-year expiration. If fully exercised, the warrants could generate additional gross proceeds of approximately $2.7 million.
The company plans to use the proceeds for research, product development, clinical studies, commercialization, and working capital.
VolitionRx (VNRX) reported strong Q3 2024 results, with revenue reaching $475,000, up 187% year-over-year. Year-to-date revenue hit $1 million, a 96% increase from the previous year. The company sold over 110,000 Nu.Q® Vet Cancer Tests in the first three quarters of 2024, with the test now available in 17 countries. Cash position stood at $5.4 million as of September 30, with an additional $2.2 million in non-dilutive funding secured from the Walloon Region, Belgium. The company aims to achieve cash neutrality in 2025.
VolitionRx (NYSE AMERICAN: VNRX) has announced a conference call scheduled for Friday, November 15 at 8:30 a.m. U.S. Eastern Time to discuss their third quarter 2024 financial and operating results, along with a business update. The call will be hosted by key executives including Louise Batchelor, Cameron Reynolds, Terig Hughes, Dr. Tom Butera, and Dr. Andrew Retter. A live audio webcast will be available, and a telephone replay will be accessible until November 29, 2024.
VolitionRx (NYSE AMERICAN: VNRX) has appointed Timothy Still as Chairman of its board of directors, effective November 06, 2024. Still brings over 35 years of experience in medical diagnostics, devices, and digital health. He previously served as President and CEO of Sense Biodetection and held leadership positions at various medical technology companies. His most recent role was at TSTILL Enterprises as Chairman and CEO, while also serving as an Operating Partner with REVIVAL Healthcare. Still holds an MBA from USC and a BS from UC Davis. The appointment comes at what the company describes as a pivotal time in its development of epigenetic technology for disease detection and monitoring.
VolitionRx (NYSE AMERICAN: VNRX) has published findings from three large, independent studies conducted in France, Germany, and the Netherlands, involving over 3,000 sepsis patients. The studies demonstrate that their Nu.Q® NETs test could predict patients at higher risk of deteriorating from sepsis by measuring levels of circulating H3.1 nucleosomes in the bloodstream. Research shows that elevated H3.1 levels are associated with increased risk of mortality, renal failure, respiratory failure, multi-organ failure, and septic shock. The company is currently seeking to commercialize Nu.Q® NETs and using these study findings to support licensing discussions with industry stakeholders.